Annual report pursuant to Section 13 and 15(d)

Intangible assets, net (Tables)

v3.22.2.2
Intangible assets, net (Tables)
12 Months Ended
May 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets

    

As of May 31,

2022

2021

Leronlimab (PRO 140) patent

$

3,500

$

3,500

ProstaGene, LLC intangible asset acquisition, net of impairment

 

2,926

Website development costs

 

20

 

20

Gross carrying value

3,520

6,446

Accumulated amortization, net of impairment

 

(3,388)

 

(4,793)

Total intangible assets, net

$

132

$

1,653